Massachusetts Financial Services Co. MA Purchases 27,155 Shares of Prelude Therapeutics Incorporated (NASDAQ:PRLD)

Massachusetts Financial Services Co. MA increased its position in Prelude Therapeutics Incorporated (NASDAQ:PRLD) by 5.2% during the third quarter, Holdings Channel.com reports. The firm owned 549,530 shares of the company’s stock after buying an additional 27,155 shares during the quarter. Massachusetts Financial Services Co. MA’s holdings in Prelude Therapeutics were worth $1,138,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. lifted its stake in shares of Prelude Therapeutics by 1.0% in the first quarter. Vanguard Group Inc. now owns 1,016,999 shares of the company’s stock valued at $4,821,000 after buying an additional 10,143 shares in the last quarter. Exchange Traded Concepts LLC lifted its position in Prelude Therapeutics by 32.2% in the 3rd quarter. Exchange Traded Concepts LLC now owns 64,409 shares of the company’s stock valued at $133,000 after acquiring an additional 15,682 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in Prelude Therapeutics by 103.2% in the 2nd quarter. Dimensional Fund Advisors LP now owns 29,074 shares of the company’s stock valued at $111,000 after acquiring an additional 14,769 shares in the last quarter. Finally, Kennedy Capital Management LLC acquired a new position in Prelude Therapeutics during the 1st quarter valued at about $119,000. Institutional investors and hedge funds own 79.72% of the company’s stock.

Prelude Therapeutics Stock Up 7.1 %

Prelude Therapeutics stock opened at $1.05 on Thursday. Prelude Therapeutics Incorporated has a 52 week low of $0.93 and a 52 week high of $6.80. The company’s 50 day moving average price is $1.60 and its two-hundred day moving average price is $3.52. The stock has a market cap of $57.78 million, a P/E ratio of -0.59 and a beta of 1.56.

Prelude Therapeutics (NASDAQ:PRLD) last issued its quarterly earnings results on Wednesday, November 6th. The company reported ($0.43) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.05. The business had revenue of $3.00 million for the quarter. On average, equities analysts anticipate that Prelude Therapeutics Incorporated will post -1.82 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on PRLD. HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of Prelude Therapeutics in a report on Friday, November 8th. JMP Securities restated a “market outperform” rating and set a $7.00 price objective on shares of Prelude Therapeutics in a research note on Monday, September 16th.

Prelude Therapeutics Profile

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion.